Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $139.00.

INSP has been the subject of a number of research analyst reports. Morgan Stanley reissued an “equal weight” rating and issued a $130.00 price target (up from $105.00) on shares of Inspire Medical Systems in a report on Tuesday, December 2nd. Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, October 27th. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, November 4th. Piper Sandler lifted their price target on shares of Inspire Medical Systems from $135.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $94.83 on Tuesday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of 64.51, a PEG ratio of 9.35 and a beta of 0.72. Inspire Medical Systems has a 12 month low of $70.77 and a 12 month high of $216.01. The stock’s 50 day moving average price is $102.90 and its 200 day moving average price is $100.33.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.53. The company had revenue of $224.50 million for the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $0.60 EPS. On average, sell-side analysts expect that Inspire Medical Systems will post 2.16 EPS for the current year.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Recent fundamentals: Inspire reported an earnings beat and year‑over‑year revenue growth (quarterly revenue +10.5%; EPS beat in November), which helps explain buying interest and the intraday uptick in the stock.
• Neutral Sentiment: Several national plaintiff firms (Faruqi & Faruqi; Bragar Eagel & Squire; Hagens Berman; Schall Law Firm; Bleichmar Fonti & Auld; The Gross Law Firm; Bronstein Gewirtz & Grossman; Hagens Berman) have issued deadline reminders for the Jan. 5, 2026 lead‑plaintiff filing — these are procedural notices encouraging eligible investors to step forward and commonly appear in the early stages of securities suits. Example notice: BusinessWire alert. BusinessWire Deadline Reminder
• Negative Sentiment: Substantive litigation risk: a class action has been filed alleging securities fraud tied to a significant prior stock drop; one complaint cites alleged concealed Medicare billing software failures and an Inspire V inventory glut — allegations that, if proven, could lead to financial exposure, management distraction and reputational harm. Investors should monitor case developments and potential disclosures. (Representative article on the alleged billing/software and inventory claims.) GlobeNewswire Litigation Summary
• Negative Sentiment: Multiple firms filing/soliciting lead‑plaintiff status increases the likelihood of sustained media attention and potential settlements or rulings—factors that can pressure the share price through legal costs, disclosure risk, or contingent liabilities. Another representative notice: AP/Bakersfield coverage. AP / Local Coverage

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Inspire Medical Systems

Hedge funds have recently bought and sold shares of the company. Dragoneer Investment Group LLC lifted its position in shares of Inspire Medical Systems by 81.4% in the 2nd quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after acquiring an additional 1,056,808 shares in the last quarter. Wasatch Advisors LP lifted its holdings in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Inspire Medical Systems by 68.7% in the third quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock valued at $96,280,000 after purchasing an additional 528,404 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Inspire Medical Systems by 214.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company’s stock worth $177,267,000 after buying an additional 759,090 shares during the period. Finally, Deerfield Management Company L.P. grew its holdings in shares of Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after buying an additional 907,694 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.